Testing two different metronidazole treatment schedule for trichomoniasis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by An Duc Thien Le |
Posted on March 22nd, 2023
|
Spironolactone is a steroid-based diuretic that has been widely used to treat hypertension. Due to its structural similarity with other hormones such as aldosterone and estrogen, many had hypothesized that it can be utilized to treat acne vulgaris. Thus, the National Institute for Health and Care Research of the United Kingdoms had sponsored a study that investigated the effect of spironolactone in treating acne.
The study included 410 women above the age of 18 years old. These women have been experiencing acne vulgaris for at least 6 months. The trial participants were randomly assigned to be treated with either spironolactone or placebo for 24 weeks. Those in the active treatment group were given 50 mg of spironolactone per day for the first 6 weeks, and the dose was increased to 100 mg until the end of the study. The patient’s skin was assessed by a dermatologist at the 12th and 24th week. The disease’s severity was judged based on the Acne-Specific Quality of Life (Acne-QoL) scale and the patient’s self-assessment. When compared to the placebo group, patients who were treated with spironolactone experience more improvement, and the benefit is more substantial at week 24 as compared to week 12. The study’s participants were asked to report any adverse events that they experienced. None of the side effects were serious and headache is the only adverse event that is significantly more common in patients treated with spironolactone. Thus, the study concluded that spironolactone is a promising addition to the current acne treating strategy.
The study included 410 women above the age of 18 years old. These women have been experiencing acne vulgaris for at least 6 months. The trial participants were randomly assigned to be treated with either spironolactone or placebo for 24 weeks. Those in the active treatment group were given 50 mg of spironolactone per day for the first 6 weeks, and the dose was increased to 100 mg until the end of the study. The patient’s skin was assessed by a dermatologist at the 12th and 24th week. The disease’s severity was judged based on the Acne-Specific Quality of Life (Acne-QoL) scale and the patient’s self-assessment. When compared to the placebo group, patients who were treated with spironolactone experience more improvement, and the benefit is more substantial at week 24 as compared to week 12. The study’s participants were asked to report any adverse events that they experienced. None of the side effects were serious and headache is the only adverse event that is significantly more common in patients treated with spironolactone. Thus, the study concluded that spironolactone is a promising addition to the current acne treating strategy.